Canada · Delayed Price · Currency is CAD PharmaCielo Statistics
Total Valuation
PharmaCielo has a market cap or net worth of CAD 8.46 million. The enterprise value is 28.84 million.
| Market Cap | 8.46M |
| Enterprise Value | 28.84M |
Important Dates
The next estimated earnings date is Monday, December 1, 2025.
| Earnings Date | Dec 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCielo has 187.98 million shares outstanding. The number of shares has increased by 6.57% in one year.
| Current Share Class | 187.98M |
| Shares Outstanding | 187.98M |
| Shares Change (YoY) | +6.57% |
| Shares Change (QoQ) | +8.17% |
| Owned by Insiders (%) | 7.98% |
| Owned by Institutions (%) | 0.18% |
| Float | 172.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.67 |
| PB Ratio | -0.89 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.17 |
| EV / Sales | 9.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 96.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.09% in the last 52 weeks. The beta is 1.65, so PharmaCielo's price volatility has been higher than the market average.
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -59.09% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 42.31 |
| Average Volume (20 Days) | 3,731 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCielo had revenue of CAD 3.17 million and -9.10 million in losses. Loss per share was -0.05.
| Revenue | 3.17M |
| Gross Profit | 373,595 |
| Operating Income | -4.72M |
| Pretax Income | -9.10M |
| Net Income | -9.10M |
| EBITDA | -3.41M |
| EBIT | -4.72M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 54,108 in cash and 22.23 million in debt, giving a net cash position of -22.18 million or -0.12 per share.
| Cash & Cash Equivalents | 54,108 |
| Total Debt | 22.23M |
| Net Cash | -22.18M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -9.49M |
| Book Value Per Share | -0.05 |
| Working Capital | -20.99M |
Cash Flow
| Operating Cash Flow | -1.69M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 11.77%, with operating and profit margins of -148.74% and -286.63%.
| Gross Margin | 11.77% |
| Operating Margin | -148.74% |
| Pretax Margin | -286.63% |
| Profit Margin | -286.63% |
| EBITDA Margin | -107.34% |
| EBIT Margin | -148.74% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCielo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.57% |
| Shareholder Yield | n/a |
| Earnings Yield | -107.52% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 18, 2019. It was a reverse split with a ratio of 0.083752.
| Last Split Date | Jan 18, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.083752 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |